Established and newly proposed mechanisms of chronic cyclosporine nephropathy

Korean Journal of Internal Medicine

Volumn 24, Issue 2, 2009, Pages 81-92

  Hye, Eun Yoon ^a   Chul, Woo Yang ^a  

^a The Catholic University of Korea   (South Korea)

Author keywords

Calcineurin inhibitor; Cyclosporine; Nephropathy; Nephrotoxicity

Indexed keywords

ALPHA TOCOPHEROL; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; BENAZEPRIL; CALCINEURIN INHIBITOR; CYCLO(DEXTRO TRYPTOPHYL DEXTRO ASPARTYLPROLYL DEXTRO VALYLLEUCYL); CYCLOSPORIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN 1; ENDOTHELIN RECEPTOR ANTAGONIST; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; KERATOEPITHELIN; LOSARTAN; MAGNESIUM; MATRIX PROTEIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NITRIC OXIDE; OSTEOPONTIN; PENTOSAN POLYSULFATE; PIRFENIDONE; PLACEBO; RECOMBINANT ERYTHROPOIETIN; ROSIGLITAZONE; SCATTER FACTOR; SPIRONOLACTONE; TOLL LIKE RECEPTOR; TRANSCRIPTION FACTOR AP 1; TRANSFORMING GROWTH FACTOR BETA ANTIBODY; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; AUTOPHAGY; CALCIUM URINE LEVEL; CELL DEATH; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; COHORT ANALYSIS; DIALYSIS; DISEASE COURSE; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG MECHANISM; DRUG WITHDRAWAL; ENDOPLASMIC RETICULUM STRESS; GENE EXPRESSION; GLOMERULUS FILTRATION RATE; HUMAN; IMMUNOREACTIVITY; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; INTERSTITIAL NEPHRITIS; ISCHEMIA; KIDNEY BLOOD FLOW; KIDNEY CONCENTRATING CAPACITY; KIDNEY DISEASE; KIDNEY GRAFT REJECTION; KIDNEY INJURY; KIDNEY TRANSPLANTATION; LONG TERM CARE; MONOTHERAPY; NEPHROTOXICITY; NONHUMAN; PATHOGENESIS; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; RECEPTOR UPREGULATION; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SIGNAL TRANSDUCTION; SODIUM RESTRICTION; TREATMENT DURATION; TUBULAR DYSFUNCTION; VASOCONSTRICTION; WASTING SYNDROME;

EID: 68549097866     PISSN: 12263303     EISSN: None     Source Type: Journal    
DOI: 10.3904/kjim.2009.24.2.81     Document Type: Review

References (145)

1. Cecka JM, Terasaki PI. The UNOS Scientific Renal Transplant Registry: 1991. Clin Transpl 1991:1-11.
2. de Mattos AM, Olyaei AJ, Bennett WM. Nephrotoxicity of immunosuppressive drugs: long-term consequences and challenges for the future. Am J Kidney Dis 2000;35:333-346.
3. Erlanger BF. Do we know the site of action of cyclosporin? Immunol Today 1992;13:487-490.
4. Shaw KT, Ho AM, Raghavan A, et al. Immunosuppressive drugs prevent a rapid dephosphorylation of transcription factor NFAT1 in stimulated immune cells. Proc Natl Acad Sci USA 1995;92:11205-11209.
5. Suthanthiran M, Morris RE, Strom TB. Immunosuppressants: cellular and molecular mechanisms of action. Am J Kidney Dis 1996;28:159-172. (Pubitemid 26286650)
6. Olyaei AJ, de Mattos AM, Bennett WM. Nephrotoxicity of immunosuppressive drugs: new insight and preventive strategies. Curr Opin Crit Care 2001;7:384-389.
7. Mourad G, Vela C, Ribstein J, Mimran A. Long-term improvement in renal function after cyclosporine reduction in renal transplant recipients with histologically proven chronic cyclosporine nephropathy. Transplantation 1998;65:661-667. (Pubitemid 28128935)
8. Myers BD, Sibley R, Newton L, et al. The long-term course of cyclosporine-associated chronic nephropathy. Kidney Int 1988;33:590-600. (Pubitemid 18073785)
9. Young BA, Burdmann EA, Johnson RJ, et al. Cellular proliferation and macrophage influx precede interstitial fibrosis in cyclosporine nephrotoxicity. Kidney Int 1995;48:439-448.
10. Young BA, Burdmann EA, Johnson RJ, et al. Cyclosporine A induced arteriolopathy in a rat model of chronic cyclosporine nephropathy. Kidney Int 1995;48:431-438.
11. Nankivell BJ, Borrows RJ, Fung CL, O'Connell PJ, Allen RD, Chapman JR. The natural history of chronic allograft nephropathy. N Engl J Med 2003;349:2326-2333. (Pubitemid 37509740)
12. Padi SS, Chopra K. Salvage of cyclosporine A-induced oxidative stress and renal dysfunction by carvedilol. Nephron 2002;92:685-692.
13. Parra T, de Arriba G, Arribas I, Perez de Lema G, Rodriguez-Puyol D, Rodriguez-Puyol M. Cyclosporine A nephrotoxicity: role of thromboxane and reactive oxygen species. J Lab Clin Med 1998;131:63-70. (Pubitemid 28065769)
14. Jenkins JK, Huang H, Ndebele K, Salahudeen AK. Vitamin E inhibits renal mRNA expression of COX II, HO I, TGFbeta, and osteopontin in the rat model of cyclosporine nephrotoxicity. Transplantation 2001;71:331-334. (Pubitemid 32126121)
15. Parra T, de Arriba G, Conejo JR, et al. Cyclosporine increases local glomerular synthesis of reactive oxygen species in rats: effect of vitamin E on cyclosporine nephrotoxicity. Transplantation 1998;66:1325-1329. (Pubitemid 28551014)
16. Burdmann EA, Andoh TF, Nast CC, et al. Prevention of experimental cyclosporin-induced interstitial fibrosis by losartan and enalapril. Am J Physiol 1995;269:F491-F499.
17. Dell K, Bohler T, Gaedeke J, Budde K, Neumayer HH, Waiser J. Impact of PGE1 on cyclosporine A induced up-regulation of TGF-beta1, its receptors, and related matrix production in cultured mesangial cells. Cytokine 2003;22:189-193. (Pubitemid 36900385)
18. Ramirez C, Olmo A, O'Valle F, et al. Role of intrarenal endothelin 1, endothelin 3, and angiotensin II expression in chronic cyclosporin A nephrotoxicity in rats. Exp Nephrol 2000;8:161-172. (Pubitemid 30313592)
19. Elzinga LW, Rosen S, Burdmann EA, Hatton DC, Lindsley J, Bennett WM. The role of renal sympathetic nerves in experimental chronic cyclosporine nephropathy. Transplantation 2000;69:2149-2153. (Pubitemid 30395052)
20. Lassila M. Interaction of cyclosporine A and the renin-angiotensin system: new perspectives. Curr Drug Metab 2002;3:61-71. (Pubitemid 34296310)
21. Yang CW, Ahn HJ, Kim WY, et al. Influence of the renin-angiotensin system on epidermal growth factor expression in normal and cyclosporine-treated rat kidney. Kidney Int 2001;60:847-857.
22. Rosen S, Greenfeld Z, Brezis M. Chronic cyclosporine-induced nephropathy in the rat: a medullary ray and inner stripe injury. Transplantation 1990;49:445-452. (Pubitemid 20088191)
23. Elzinga LW, Rosen S, Bennett WM. Dissociation of glomerular filtration rate from tubulointerstitial fibrosis in experimental chronic cyclosporine nephropathy: role of sodium intake. J Am Soc Nephrol 1993;4:214-221.
24. Mazzali M, Kim YG, Suga S, et al. Hyperuricemia exacerbates chronic cyclosporine nephropathy. Transplantation 2001;71:900-905. (Pubitemid 32417351)
25. Yang CW, Ahn HJ, Kim WY, et al. Synergistic effects of mycophenolate mofetil and losartan in a model of chronic cyclosporine nephropathy. Transplantation 2003;75:309-315.
26. Thomas SE, Andoh TF, Pichler RH, et al. Accelerated apoptosis characterizes cyclosporine-associated interstitial fibrosis. Kidney Int 1998;53:897-908.
27. Shihab FS, Bennett WM, Tanner AM, Andoh TF. Angiotensin II blockade decreases TGF-beta1 and matrix proteins in cyclosporine nephropathy. Kidney Int 1997;52:660-673.
28. Pichler RH, Franceschini N, Young BA, et al. Pathogenesis of cyclosporine nephropathy: roles of angiotensin II and osteopontin. J Am Soc Nephrol 1995;6:1186-1196.
29. Li C, Yang CW, Park CW, et al. Long-term treatment with ramipril attenuates renal osteopontin expression in diabetic rats. Kidney Int 2003;63:454-463. (Pubitemid 36126792)
30. Kuro-o M, Matsumura Y, Aizawa H, et al. Mutation of the mouse klotho gene leads to a syndrome resembling' ageing. Nature 1997;390:45-51. (Pubitemid 27494749)
31. Koh N, Fujimori T, Nishiguchi S, et al. Severely reduced production of klotho in human chronic renal failure kidney. Biochem Biophys Res Commun 2001;280:1015-1020. (Pubitemid 32924441)
32. Sugiura H, Yoshida T, Tsuchiya K, et al. Klotho reduces apoptosis in experimental ischaemic acute renal failure. Nephrol Dial Transplant 2005;20:2636-2645. (Pubitemid 41672261)
33. Kone BC, Baylis C. Biosynthesis and homeostatic roles of nitric oxide in the normal kidney. Am J Physiol 1997;272:F561-F578. (Pubitemid 27382204)
34. Diederich D, Yang Z, Luscher TF. Chronic cyclosporine therapy impairs endothelium-dependent relaxation in the renal artery of the rat. J Am Soc Nephrol 1992;2:1291-1297.
35. Stroes ES, Luscher TF, de Groot FG, Koomans HA, Rabelink TJ. Cyclosporin A increases nitric oxide activity in vivo. Hypertension 1997;29:570-575. (Pubitemid 27074720)
36. Takenaka T, Hashimoto Y, Epstein M. Diminished acetylcholine-induced vasodilation in renal microvessels of cyclosporine-treated rats. J Am Soc Nephrol 1992;3:42-50.
37. Bobadilla NA, Gamba G, Tapia E, et al. Role of NO in cyclosporin nephrotoxicity: effects of chronic NO inhibition and NO synthases gene expression. Am J Physiol 1998;274:F791-F798. (Pubitemid 28217798)
38. Yang CW, Kim YS, Kim J, et al. Oral supplementation of L-arginine prevents chronic cyclosporine nephrotoxicity in rats. Exp Nephrol 1998;6:50-56. (Pubitemid 28096337)
39. Shihab FS, Bennett WM, Isaac J, Yi H, Andoh TF. Nitric oxide modulates vascular endothelial growth factor and receptors in chronic cyclosporine nephrotoxicity. Kidney Int 2003;63:522-533. (Pubitemid 36126798)
40. Shihab FS, Yi H, Bennett WM, Andoh TF. Effect of nitric oxide modulation on TGF-beta1 and matrix proteins in chronic cyclosporine nephrotoxicity. Kidney Int 2000;58:1174-1185. (Pubitemid 30678040)
41. Butler WT. Structural and functional domains of osteopontin. Ann N Y Acad Sci 1995;760:6-11.
42. Brown LF, Papadopoulos-Sergiou A, Berse B, et al. Osteopontin expression and distribution in human carcinomas. Am J Pathol 1994;145:610-623. (Pubitemid 24285968)
43. Giachelli C, Bae N, Lombardi D, Majesky M, Schwartz S. Molecular cloning and characterization of 2B7, a rat mRNA which distinguishes smooth muscle cell phenotypes in vitro and is identical to osteopontin (secreted phosphoprotein I, 2aR). Biochem Biophys Res Commun 1991;177:867-873.
44. Giachelli CM, Liaw L, Murry CE, Schwartz SM, Almeida M. Osteopontin expression in cardiovascular diseases. Ann N Y Acad Sci 1995;760:109-126.
45. Hudkins KL, Giachelli CM, Cui Y, Couser WG, Johnson RJ, Alpers CE. Osteopontin expression in fetal and mature human kidney. J Am Soc Nephrol 1999;10:444-457. (Pubitemid 29117625)
46. Lopez CA, Hoyer JR, Wilson PD, Waterhouse P, Denhardt DT. Heterogeneity of osteopontin expression among nephrons in mouse kidneys and enhanced expression in sclerotic glomeruli. Lab Invest 1993;69:355-363. (Pubitemid 23315722)
47. Patarca R, Freeman GJ, Singh RP, et al. Structural and functional studies of the early T lymphocyte activation 1 (Eta-1) gene: definition of a novel T cell-dependent response associated with genetic resistance to bacterial infection. J Exp Med 1989;170:145-161. (Pubitemid 19179701)
48. Hu DD, Lin EC, Kovach NL, Hoyer JR, Smith JW. A biochemical characterization of the binding of osteopontin to integrins alpha vbeta 1 and alpha vbeta 5. J Biol Chem 1995;270:26232-26238.
49. Weber GF, Ashkar S, Glimcher MJ, Cantor H. Receptor-ligand interaction between CD44 and osteopontin (Eta-1). Science 1996;271:509-512. (Pubitemid 26044470)
50. Singh RP, Patarca R, Schwartz J, Singh P, Cantor H. Definition of a specific interaction between the early T lymphocyte activation 1 (Eta-1) protein and murine macrophages in vitro and its effect upon macrophages in vivo. J Exp Med 1990;171:1931-1942.
51. Ophascharoensuk V, Giachelli CM, Gordon K, et al. Obstructive uropathy in the mouse: role of osteopontin in interstitial fibrosis and apoptosis. Kidney Int 1999;56:571-580. (Pubitemid 29353155)
52. Magil AB, Pichler RH, Johnson RJ. Osteopontin in chronic puromycin aminonucleoside nephrosis. J Am Soc Nephrol 1997;8:1383-1390.
53. Pichler R, Giachelli CM, Lombardi D, et al. Tubulointerstitial disease in glomerulonephritis: potential role of osteopontin (uropontin). Am J Pathol 1994;144:915-926. (Pubitemid 24160633)
54. Wuthrich RP, Fan X, Ritthaler T, et al. Enhanced osteopontin expression and macrophage infiltration in MRL-Fas(lpr) mice with lupus nephritis. Autoimmunity 1998;28:139-150. (Pubitemid 29027564)
55. Yu XQ, Wu LL, Huang XR, et al. Osteopontin expression in progressive renal injury in remnant kidney: role of angiotensin II. Kidney Int 2000;58:1469-1480.
56. Li C, Yang CW, Ahn HJ, et al. Colchicine suppresses osteopontin expression and inflammatory cell infiltration in chronic cyclosporine nephrotoxicity. Nephron 2002;92:422-430.
57. Mazzali M, Hughes J, Dantas M, et al. Effects of cyclosporine in osteopontin null mice. Kidney Int 2002;62:78-85. (Pubitemid 34754050)
58. Shihab FS, Andoh TF, Tanner AM, Bennett WM. Sodium depletion enhances fibrosis and the expression of TGF-beta1 and matrix proteins in experimental chronic cyclosporine nephropathy. Am J Kidney Dis 1997;30:71-81.
59. Shihab FS, Bennett WM, Yi H, Andoh TF. Pirfenidone treatment decreases transforming growth factor-beta1 and matrix proteins and ameliorates fibrosis in chronic cyclosporine nephrotoxicity. Am J Transplant 2002;2:111-119. (Pubitemid 36306789)
60. Ling H, Li X, Jha S, et al. Therapeutic role of TGF-beta-neutralizing antibody in mouse cyclosporin A nephropathy: morphologic improvement associated with functional preservation. J Am Soc Nephrol 2003;14:377-388. (Pubitemid 36150861)
61. O'Connor-McCourt MD, Wakefield LM. Latent transforming growth factor-beta in serum: a specific complex with alpha 2-macroglobulin. J Biol Chem 1987;262:14090-14099.
62. Oreffo RO, Mundy GR, Seyedin SM, Bonewald LF. Activation of the bone-derived latent TGF beta complex by isolated osteoclasts. Biochem Biophys Res Commun 1989;158:817-823.
63. Schultz-Cherry S, Chen H, Mosher DF, et al. Regulation of transforming growth factor-beta activation by discrete sequences of thrombospondin 1. J Biol Chem 1995;270:7304-7310.
64. Sharma K, Ziyadeh FN. The transforming growth factor-beta system and the kidney. Semin Nephrol 1993;13:116-128. (Pubitemid 23020248)
65. Yamaguchi Y, Mann DM, Ruoslahti E. Negative regulation of transforming growth factor-beta by the proteoglycan decorin. Nature 1990;346:281-284. (Pubitemid 20227409)
66. Skonier J, Neubauer M, Madisen L, Bennett K, Plowman GD, Purchio AF. cDNA cloning and sequence analysis of beta ig-h3, a novel gene induced in a human adenocarcinoma cell line after treatment with transforming growth factor-beta. DNA Cell Biol 1992;11:511-522.
67. Billings PC, Whitbeck JC, Adams CS, et al. The transforming growth factor-beta-inducible matrix protein (beta)ig-h3 interacts with fibronectin. J Biol Chem 2002;277:28003-28009.
68. Billings PC, Herrick DJ, Kucich U, et al. Extracellular matrix and nuclear localization of beta ig-h3 in human bladder smooth muscle and fibroblast cells. J Cell Biochem 2000;79:261-273. (Pubitemid 30729097)
69. Gibson MA, Kumaratilake JS, Cleary EG. Immunohistochemical and ultrastructural localization of MP78/70 (betaig-h3) in extracellular matrix of developing and mature bovine tissues. J Histochem Cytochem 1997;45:1683-1696.
70. O'Brien ER, Bennett KL, Garvin MR, et al. Beta ig-h3, a transforming growth factor-beta-inducible gene, is overexpressed in atherosclerotic and restenotic human vascular lesions. Arterioscler Thromb Vasc Biol 1996;16:576-584.
71. Langham RG, Egan MK, Dowling JP, Gilbert RE, Thomson NM. Transforming growth factor-beta1 and tumor growth factor-beta-inducible gene-H3 in nonrenal transplant cyclosporine nephropathy. Transplantation 2001;72:1826-1829.
72. Sun BK, Li C, Lim SW, et al. Expression of transforming growth factor-beta-inducible gene-h3 in normal and cyclosporine-treated rat kidney. J Lab Clin Med 2004;143:175-183. (Pubitemid 38352539)
73. Yang CW, Faulkner GR, Wahba IM, et al. Expression of apoptosis-related genes in chronic cyclosporine nephrotoxicity in mice. Am J Transplant 2002;2:391-399.
74. Ito H, Kasagi N, Shomori K, Osaki M, Adachi H. Apoptosis in the human allografted kidney: analysis by terminal deoxynucleotidyl transferase-mediated DUTP-botin nick end labeling. Transplantation 1995;60:794-798.
75. Ortiz A, Lorz C, Catalan MP, Justo P, Egido J. Role and regulation of apoptotic cell death in the kidney: Y2K update. Front Biosci 2000;5:D735-D749.
76. Li C, Yang CW, Ahn HJ, et al. Colchicine decreases apoptotic cell death in chronic cyclosporine nephrotoxicity. J Lab Clin Med 2002;139:364-371. (Pubitemid 34604658)
77. Ying S, Khan LN, Meng Q, Barnes NC, Kay AB. Cyclosporin A, apoptosis of BAL T-cells and expression of Bcl-2 in asthmatics. Eur Respir J 2003;22:207-212. (Pubitemid 36986986)
78. Healy E, Dempsey M, Lally C, Ryan MP. Apoptosis and necrosis: mechanisms of cell death induced by cyclosporine A in a renal proximal tubular cell line. Kidney Int 1998;54:1955-1966. (Pubitemid 28533623)
79. Ortiz A, Lorz C, Catalan M, Coca S, Egido J. Cyclosporine A induces apoptosis in murine tubular epithelial cells: role of caspases. Kidney Int Suppl 1998;68:825-829. (Pubitemid 28531771)
80. Shihab FS, Andoh TF, Tanner AM, Yi H, Bennett WM. Expression of apoptosis regulatory genes in chronic cyclosporine nephrotoxicity favors apoptosis. Kidney Int 1999;56:2147-2159. (Pubitemid 30004743)
81. Amore A, Emancipator SN, Cirina P, et al. Nitric oxide mediates cyclosporine-induced apoptosis in cultured renal cells. Kidney Int 2000;57:1549-1559. (Pubitemid 30207913)
82. Li C, Lim SW, Sun BK, et al. Expression of apoptosis-related factors in chronic cyclosporine nephrotoxicity after cyclosporine withdrawal. Acta Pharmacol Sin 2004;25:401-411. (Pubitemid 38470406)
83. Ghee JY, Han DH, Song HK, et al. The role of macrophage in the pathogenesis of chronic cyclosporine-induced nephropathy. Nephrol Dial Transplant 2008;23:4061-4069.
84. Guijarro C, Egido J. Transcription factor-kappa B (NF-kappa B) and renal disease. Kidney Int 2001;59:415-424. (Pubitemid 32157906)
85. Barnes PJ, Karin M. Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 1997;336:1066-1071. (Pubitemid 27163860)
86. Karin M, Liu Z, Zandi E. AP-1 function and regulation. Curr Opin Cell Biol 1997;9:240-246.
87. Tamada S, Nakatani T, Asai T, et al. Inhibition of nuclear factor-kappaB activation by pyrrolidine dithiocarbamate prevents chronic FK506 nephropathy. Kidney Int 2003;63:306-314. (Pubitemid 35463935)
88. Klahr S, Morrissey JJ. The role of vasoactive compounds, growth factors and cytokines in the progression of renal disease. Kidney Int Suppl 2000;75:S7-S14. (Pubitemid 30205433)
89. Mezzano SA, Barria M, Droguett MA, et al. Tubular NF-kappaB and AP-1 activation in human proteinuric renal disease. Kidney Int 2001;60:1366-1377. (Pubitemid 32960030)
90. Ruiz-Ortega M, Bustos C, Hernandez-Presa MA, Lorenzo O, Plaza JJ, Egido J. Angiotensin II participates in mononuclear cell recruitment in experimental immune complex nephritis through nuclear factor-kappa B activation and monocyte chemoattractant protein-1 synthesis. J Immunol 1998;161:430-439. (Pubitemid 28285552)
91. Asai T, Nakatani T, Tamada S, et al. Activation of transcription factors AP-1 and NF-kappaB in chronic cyclosporine A nephrotoxicity: role in beneficial effects of magnesium supplementation. Transplantation 2003;75:1040-1044. (Pubitemid 36438535)
92. Lim SW, Li C, Ahn KO, et al. Cyclosporine-induced renal injury induces toll-like receptor and maturation of dendritic cells. Transplantation 2005;80:691-699. (Pubitemid 41379412)
93. Akira S, Takeda K, Kaisho T. Toll-like receptors: critical proteins linking innate and acquired immunity. Nat Immunol 2001;2:675-680. (Pubitemid 32747155)
94. Janeway CA Jr, Medzhitov R. Innate immune recognition. Annu Rev Immunol 2002;20:197-216.
95. Anders HJ, Banas B, Schlondorff D. Signaling danger: toll-like receptors and their potential roles in kidney disease. J Am Soc Nephrol 2004;15:854-867. (Pubitemid 38375304)
96. Kumaraguru U, Pack CD, Rouse BT. Toll-like receptor ligand links innate and adaptive immune responses by the production of heat-shock proteins. J Leukoc Biol 2003;73:574-583. (Pubitemid 38040469)
97. Vabulas RM, Ahmad-Nejad P, Ghose S, Kirschning CJ, Issels RD, Wagner H. HSP70 as endogenous stimulus of the Toll/interleukin-1 receptor signal pathway. J Biol Chem 2002;277:15107-15112. (Pubitemid 34952589)
98. Nielsen S, Kwon TH, Christensen BM, Promeneur D, Frokiaer J, Marples D. Physiology and pathophysiology of renal aquaporins. J Am Soc Nephrol 1999;10:647-663.
99. Wintour EM. Water channels and urea transporters. Clin Exp Pharmacol Physiol 1997;24:1-9.
100. Kishore BK, Krane CM, Di Iulio D, Menon AG, Cacini W. Expression of renal aquaporins 1, 2, and 3 in a rat model of cisplatin-induced polyuria. Kidney Int 2000;58:701-711.
101. Nielsen S, Frokiaer J, Marples D, Kwon TH, Agre P, Knepper MA. Aquaporins in the kidney: from molecules to medicine. Physiol Rev 2002;82:205-244.
102. Sands JM. Regulation of renal urea transporters. J Am Soc Nephrol 1999;10:635-646.
103. Bradford AD, Terris JM, Ecelbarger CA, et al. 97- and 117-kDa forms of collecting duct urea transporter UT-A1 are due to different states of glycosylation. Am J Physiol Renal Physiol 2001;281:F133-F143. (Pubitemid 32911879)
104. Terris JM, Knepper MA, Wade JB. UT-A3: localization and characterization of an additional urea transporter isoform in the IMCD. Am J Physiol Renal Physiol 2001;280:F325-F332. (Pubitemid 32473287)
105. Timmer RT, Klein JD, Bagnasco SM, et al. Localization of the urea transporter UT-B protein in human and rat erythrocytes and tissues. Am J Physiol Cell Physiol 2001;281:C1318-C1325. (Pubitemid 32948121)
106. Wade JB, Lee AJ, Liu J, et al. UT-A2: a 55-kDa urea transporter in thin descending limb whose abundance is regulated by vasopressin. Am J Physiol Renal Physiol 2000;278:F52-F62. (Pubitemid 30106125)
107. Lim SW, Li C, Sun BK, et al. Long-term treatment with cyclosporine decreases aquaporins and urea transporters in the rat kidney. Am J Physiol Renal Physiol 2004;287:F139-F151. (Pubitemid 38780593)
108. Lim SW, Ahn KO, Sheen MR, et al. Downregulation of renal sodium transporters and tonicity-responsive enhancer binding protein by long-term treatment with cyclosporin A. J Am Soc Nephrol 2007;18:421-429.
109. Stier CT Jr, Itskovitz HD. Renal calcium metabolism and diuretics. Annu Rev Pharmacol Toxicol 1986;26:101-116.
110. Gross M, Kumar R. Physiology and biochemistry of vitamin D-dependent calcium binding proteins. Am J Physiol 1990;259:F195-F209. (Pubitemid 20257477)
111. Staun M, Sjostrom H, Noren O. Calcium-binding protein from human small intestine: purification and characterization of a 10,000 molecular weight protein. Eur J Clin Invest 1986;16:468-472. (Pubitemid 17212521)
112. Roth J, Brown D, Norman AW, Orci L. Localization of the vitamin D-dependent calcium-binding protein in mammalian kidney. Am J Physiol 1982;243:F243-F252. (Pubitemid 12037811)
113. Yang CW, Kim J, Kim YH, et al. Inhibition of calbindin D28K expression by cyclosporin A in rat kidney: the possible pathogenesis of cyclosporin A-induced hypercalciuria. J Am Soc Nephrol 1998;9:1416-1426. (Pubitemid 28354551)
114. Steiner S, Aicher L, Raymackers J, et al. Cyclosporine A decreases the protein level of the calcium-binding protein calbindin-D 28kDa in rat kidney. Biochem Pharmacol 1996;51:253-258. (Pubitemid 26053570)
115. Zhang K, Kaufman RJ. The unfolded protein response: a stress signaling pathway critical for health and disease. Neurology 2006;66(2 Suppl 1):S102-S109. (Pubitemid 43739994)
116. Okada K, Minamino T, Tsukamoto Y, et al. Prolonged endoplasmic reticulum stress in hypertrophic and failing heart after aortic constriction: possible contribution of endoplasmic reticulum stress to cardiac myocyte apoptosis. Circulation 2004;110:705-712. (Pubitemid 39056270)
117. Oyadomari S, Araki E, Mori M. Endoplasmic reticulum stress-mediated apoptosis in pancreatic beta-cells. Apoptosis 2002;7:335-345. (Pubitemid 34832258)
118. Pallet N, Bouvier N, Bendjallabah A, et al. Cyclosporine-induced endoplasmic reticulum stress triggers tubular phenotypic changes and death. Am J Transplant 2008;8:2283-2296.
119. Pallet N, Bouvier N, Legendre C, et al. Autophagy protects renal tubular cells against cyclosporine toxicity. Autophagy 2008;4:783-791.
120. Ding WX, Ni HM, Gao W, et al. Linking of autophagy to ubiquitin-proteasome system is important for the regulation of endoplasmic reticulum stress and cell viability. Am J Pathol 2007;171:513-524. (Pubitemid 47344684)
121. Hoyer-Hansen M, Jaattela M. Connecting endoplasmic reticulum stress to autophagy by unfolded protein response and calcium. Cell Death Differ 2007;14:1576-1582. (Pubitemid 47278843)
122. Moretti L, Cha YI, Niermann KJ, Lu B. Switch between apoptosis and autophagy: radiation-induced endoplasmic reticulum stress? Cell Cycle 2007;6:793-798.
123. Han SW, Li C, Ahn KO, et al. Prolonged endoplasmic reticulum stress induces apoptotic cell death in an experimental model of chronic cyclosporine nephropathy. Am J Nephrol 2008;28:707-714.
124. Weir MR, Ward MT, Blahut SA, et al. Long-term impact of discontinued or reduced calcineurin inhibitor in patients with chronic allograft nephropathy. Kidney Int 2001;59:1567-1573.
125. Franceschini N, Alpers CE, Bennett WM, Andoh TF. Cyclosporine arteriolopathy: effects of drug withdrawal. Am J Kidney Dis 1998;32:247-253. (Pubitemid 28364327)
126. Li C, Yang CW, Kim WY, et al. Reversibility of chronic cyclosporine nephropathy in rats after withdrawal of cyclosporine. Am J Physiol Renal Physiol 2003;284:F389-F398. (Pubitemid 36114702)
127. Ahn KO, Lim SW, Li C, et al. Influence of angiotensin II on expression of toll-like receptor 2 and maturation of dendritic cells in chronic cyclosporine nephropathy. Transplantation 2007;83:938-947. (Pubitemid 46682736)
128. Hunley TE, Fogo A, Iwasaki S, Kon V. Endothelin A receptor mediates functional but not structural damage in chronic cyclosporine nephrotoxicity. J Am Soc Nephrol 1995;5:1718-1723.
129. Li C, Yang CW, Park JH, et al. Pravastatin treatment attenuates interstitial inflammation and fibrosis in a rat model of chronic cyclosporine-induced nephropathy. Am J Physiol Renal Physiol 2004;286:F46-F57. (Pubitemid 38045041)
130. Shihab FS, Bennett WM, Yi H, Andoh TF. Effect of pirfenidone on apoptosis-regulatory genes in chronic cyclosporine nephrotoxicity. Transplantation 2005;79:419-426. (Pubitemid 40280173)
131. Mizui M, Isaka Y, Takabatake Y, et al. Electroporation-mediated HGF gene transfer ameliorated cyclosporine nephrotoxicity. Kidney Int 2004;65:2041-2053. (Pubitemid 38669990)
132. Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature 1990;343:425-430.
133. Faggiotto A, Paoletti R. State-of-the-Art lecture: statins and blockers of the renin-angiotensin system: vascular protection beyond their primary mode of action. Hypertension 1999;34:987-996. (Pubitemid 29501335)
134. Rosenson RS, Tangney CC. Antiatherothrombotic properties of statins: implications for cardiovascular event reduction. JAMA 1998;279:1643-1650.
135. Joyce M, Kelly C, Winter D, Chen G, Leahy A, Bouchier-Hayes D. Pravastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, attenuates renal injury in an experimental model of ischemia-reperfusion. J Surg Res 2001;101:79-84. (Pubitemid 33030111)
136. Kim SI, Han DC, Lee HB. Lovastatin inhibits transforming growth factor-beta1 expression in diabetic rat glomeruli and cultured rat mesangial cells. J Am Soc Nephrol 2000;11:80-87. (Pubitemid 30020429)
137. Harris KP, Purkerson ML, Yates J, Klahr S. Lovastatin ameliorates the development of glomerulosclerosis and uremia in experimental nephrotic syndrome. Am J Kidney Dis 1990;15:16-23. (Pubitemid 20086576)
138. Moriyama T, Kawada N, Nagatoya K, et al. Fluvastatin suppresses oxidative stress and fibrosis in the interstitium of mouse kidneys with unilateral ureteral obstruction. Kidney Int 2001;59:2095-2103. (Pubitemid 32467601)
139. Schwedler SB, Bobadilla N, Striker LJ, Vaamonde CA, Herrera-Acosta J, Striker GE. Pentosan polysulfate treatment reduces cyclosporine-induced nephropathy in salt-depleted rats. Transplantation 1999;68:1583-1588.
140. Yang CW, Ahn HJ, Kim WY, et al. Cyclosporine withdrawal and mycophenolate mofetil treatment effects on the progression of chronic cyclosporine nephrotoxicity. Kidney Int 2002;62:20-30. (Pubitemid 34754044)
141. Lee SH, Li C, Lim SW, et al. Attenuation of interstitial inflammation and fibrosis by recombinant human erythropoietin in chronic cyclosporine nephropathy. Am J Nephrol 2005;25:64-76. (Pubitemid 40529278)
142. Ahn KO, Lim SW, Yang HJ, et al. Induction of PPAR gamma mRNA and protein expression by rosiglitazone in chronic cyclosporine nephropathy in the rat. Yonsei Med J 2007;48:308-316.
143. Chung BH, Li C, Sun BK, et al. Rosiglitazone protects against cyclosporine-induced pancreatic and renal injury in rats. Am J Transplant 2005;5:1856-1867. (Pubitemid 41039858)
144. Feria I, Pichardo I, Juarez P, et al. Therapeutic benefit of spironolactone in experimental chronic cyclosporine A nephrotoxicity. Kidney Int 2003;63:43-52. (Pubitemid 35463905)
145. Perez-Rojas JM, Derive S, Blanco JA, et al. Renocortical mRNA expression of vasoactive factors during spironolactone protective effect in chronic cyclosporine nephrotoxicity. Am J Physiol Renal Physiol 2005;289:F1020-F1030. (Pubitemid 41447057)